Stocks News

LAST PRICE
895.0200
TODAY'S CHANGE (%)
Trending Up1.0300 (0.1152%)

Bid / Lots
893.2800/ 4
Ask / Lots
895.0700/ 4
Open / Previous Close
913.9700 / 893.9900
Day Range
Low 894.4400
High 920.7300
52 Week Range
Low 684.8050
High 998.3250
Volume
137,426
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN), from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: REGN
  
  Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
  
  NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
- Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:02AM ET on Thursday Apr 18, 2024 by Dow Jones
  11:02AM ET on Thursday Apr 18, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 8:02AM ET on Thursday Apr 18, 2024 by Dow Jones
  8:02AM ET on Thursday Apr 18, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  LOS ANGELES, CA / ACCESSWIRE / April 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws.
- DJ Regeneron Pharma Is Maintained at Buy by UBS, from 7:43AM ET on Thursday Apr 18, 2024 by Dow Jones
  7:43AM ET on Thursday Apr 18, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 18, 2024 07:43 ET (11:43 GMT)
Apr 17, 2024
- REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Wednesday Apr 17, 2024 by Dow Jones
  9:00PM ET on Wednesday Apr 17, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm

Today
- --Needham Adjusts Price Target on Biogen to $294 From $300, from 1 hour ago by MT Newswires
  1 hour ago by MT Newswires
  Companies Mentioned: BIIB
- --BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: BIIB
- --Oppenheimer Adjusts Biogen Price Target to $270 From $290, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: BIIB
Yesterday
- Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain, from 10:12AM ET on Thursday Apr 18, 2024 by MT Newswires
  10:12AM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: VRTX
Apr 17, 2024
- --UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating, from 10:08AM ET on Wednesday Apr 17, 2024 by MT Newswires
  10:08AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: VRTX
- --UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating, from 9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires
  9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: BIIB
- --Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445, from 8:09AM ET on Wednesday Apr 17, 2024 by MT Newswires
  8:09AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: VRTX
- --Wedbush Cuts Biogen's Price Target to $213 From $245, from 7:25AM ET on Wednesday Apr 17, 2024 by MT Newswires
  7:25AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: BIIB
Apr 16, 2024
- Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing, from 4:25PM ET on Tuesday Apr 16, 2024 by MT Newswires
  4:25PM ET on Tuesday Apr 16, 2024 by MT Newswires
  Companies Mentioned: MRNA
Apr 15, 2024
- --Argus Adjusts Biogen's Price Target to $240 From $315, from 7:39AM ET on Monday Apr 15, 2024 by MT Newswires
  7:39AM ET on Monday Apr 15, 2024 by MT Newswires
  Companies Mentioned: BIIB

Regeneron Pharmaceuticals Inc
NASDAQ:REGNUnited States

Search Criteria

Yesterday

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN), from 18 hours ago by Dow Jones

Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:02AM ET on Thursday Apr 18, 2024 by Dow Jones

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 8:02AM ET on Thursday Apr 18, 2024 by Dow Jones

DJ Regeneron Pharma Is Maintained at Buy by UBS, from 7:43AM ET on Thursday Apr 18, 2024 by Dow Jones

Apr 17, 2024

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Wednesday Apr 17, 2024 by Dow Jones

Peers Headlines

Today

--Needham Adjusts Price Target on Biogen to $294 From $300, from 1 hour ago by MT Newswires

--BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept, from 2 hours ago by MT Newswires

--Oppenheimer Adjusts Biogen Price Target to $270 From $290, from 3 hours ago by MT Newswires

Yesterday

Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain, from 10:12AM ET on Thursday Apr 18, 2024 by MT Newswires

Apr 17, 2024

--UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating, from 10:08AM ET on Wednesday Apr 17, 2024 by MT Newswires

--UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating, from 9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires

--Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445, from 8:09AM ET on Wednesday Apr 17, 2024 by MT Newswires

--Wedbush Cuts Biogen's Price Target to $213 From $245, from 7:25AM ET on Wednesday Apr 17, 2024 by MT Newswires

Apr 16, 2024

Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing, from 4:25PM ET on Tuesday Apr 16, 2024 by MT Newswires

Apr 15, 2024

--Argus Adjusts Biogen's Price Target to $240 From $315, from 7:39AM ET on Monday Apr 15, 2024 by MT Newswires